Related references
Note: Only part of the references are listed.Bioanalytical Approaches to Quantify Total and Free Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development
Jean W. Lee et al.
AAPS JOURNAL (2011)
A Dual-Monoclonal Sandwich ELISA Specific for Hepcidin-25
Anthony M. Butterfield et al.
CLINICAL CHEMISTRY (2010)
Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand
Hossein Salimi-Moosavi et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2010)
Fresh from the biologic pipeline-2009
Cormac Sheridan
NATURE BIOTECHNOLOGY (2010)
Fit-for-Purpose Method Validation and Application of a Biomarker (C-terminal Telopeptides of Type 1 Collagen) in Denosumab Clinical Studies
Jin Wang et al.
AAPS JOURNAL (2009)
Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent
Anthony J. Mutsaers et al.
CLINICAL CANCER RESEARCH (2009)
A novel method for quantitative measurement of a biomarker in the presence of a therapeutic monoclonal antibody directed against the biomarker
R. Aleks Davis et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline
Amanda G. Paulovich et al.
PROTEOMICS CLINICAL APPLICATIONS (2008)
Promises of biomarkers in drug development a reality check
Estelle Marrer et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
Naoto Hayashi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Changes in humoral responses to β-lactoglobulin in tolerant patients suggest a particular role for IgG4 in delayed, non-IgE-mediated cow's milk allergy
Gaynour B. G. Sletten et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2006)
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Nader Rifai et al.
NATURE BIOTECHNOLOGY (2006)
Fit-for-purpose method development and validation for successful biomarker measurement
JW Lee et al.
PHARMACEUTICAL RESEARCH (2006)
Covered stent septal ablation for hypertrophic obstruction cardiomyopathy
A Anzuini et al.
CIRCULATION (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules
B DeSilva et al.
PHARMACEUTICAL RESEARCH (2003)
Towards a better understanding of heterophile (and the like) antibody interference with modem immunoassays
SS Levinson et al.
CLINICA CHIMICA ACTA (2002)
Share Paper
